📊 CTOR Key Takeaways
Is Citius Oncology, Inc.. (CTOR) a Good Investment?
Citius Oncology is a pre-commercial stage pharmaceutical company with minimal revenue generation ($3.9M) and substantial operating losses (-$5.3M). The company is burning cash at an unsustainable rate (-$7.4M operating cash flow) with only $7.3M in cash reserves, creating severe liquidity concerns. Without meaningful revenue growth or a clear path to profitability, the company faces existential funding risks.
Citius Oncology's fundamentals are weak: despite an 80.0% gross margin, the business is generating only $3.94M in revenue while posting operating and net margins worse than -130%, indicating the cost structure is far from sustainable. Financial health is also pressured by negative operating cash flow, sub-1.0 current ratio, and limited cash relative to liabilities, which raises concern about near-term funding needs even though balance-sheet leverage is low.
Why Buy Citius Oncology, Inc.. Stock? CTOR Key Strengths
- High gross margin (80%) on limited revenue suggests strong pricing power if commercialization succeeds
- Positive stockholders' equity ($58.4M) provides some balance sheet cushion
- Low debt burden (0.00x Debt/Equity) avoids near-term refinancing pressure
- High gross margin suggests attractive unit economics if revenue scales
- No meaningful long-term debt reduces balance-sheet leverage risk
- Positive equity base provides some balance-sheet support
CTOR Stock Risks: Citius Oncology, Inc.. Investment Risks
- Critical liquidity crisis: current ratio of 0.83x and quick ratio of 0.32x indicate inability to cover near-term obligations
- Severe cash burn rate: -$7.4M operating cash flow with only $7.3M cash equivalents implies less than 1 year of runway at current burn rate
- No revenue growth trajectory: $3.9M annual revenue is insufficient to support R&D operations; company is entirely dependent on capital infusion
- Negative profitability across all metrics with -140.3% net margin and -186.5% free cash flow margin
- Early-stage pharma with no demonstrated commercial success or pipeline visibility in available data
- Severe operating and net losses show the business is not yet economically viable at current scale
- Weak liquidity with a 0.83x current ratio and 0.32x quick ratio increases financing risk
- Negative operating cash flow and free cash flow point to continued cash burn
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Clinical trial progress and regulatory milestones for pipeline assets
- Revenue growth rate and customer acquisition from commercialization efforts
- Future capital raise announcements and dilution impact
- Operating cash flow trajectory and path to cash flow breakeven
- Operating cash burn relative to cash balance
- Revenue growth and operating margin improvement
Citius Oncology, Inc.. (CTOR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CTOR Profit Margin, ROE & Profitability Analysis
CTOR vs Healthcare Sector: How Citius Oncology, Inc.. Compares
How Citius Oncology, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Citius Oncology, Inc.. Stock Overvalued? CTOR Valuation Analysis 2026
Based on fundamental analysis, Citius Oncology, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Citius Oncology, Inc.. Balance Sheet: CTOR Debt, Cash & Liquidity
CTOR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Citius Oncology, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.31 indicates the company is currently unprofitable.
CTOR Revenue Growth, EPS Growth & YoY Performance
CTOR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.9M | -$5.5M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Citius Oncology, Inc.. Dividends, Buybacks & Capital Allocation
CTOR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Citius Oncology, Inc.. (CIK: 0001851484)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTOR
What is the AI rating for CTOR?
Citius Oncology, Inc.. (CTOR) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTOR's key strengths?
Claude: High gross margin (80%) on limited revenue suggests strong pricing power if commercialization succeeds. Positive stockholders' equity ($58.4M) provides some balance sheet cushion. ChatGPT: High gross margin suggests attractive unit economics if revenue scales. No meaningful long-term debt reduces balance-sheet leverage risk.
What are the risks of investing in CTOR?
Claude: Critical liquidity crisis: current ratio of 0.83x and quick ratio of 0.32x indicate inability to cover near-term obligations. Severe cash burn rate: -$7.4M operating cash flow with only $7.3M cash equivalents implies less than 1 year of runway at current burn rate. ChatGPT: Severe operating and net losses show the business is not yet economically viable at current scale. Weak liquidity with a 0.83x current ratio and 0.32x quick ratio increases financing risk.
What is CTOR's revenue and growth?
Citius Oncology, Inc.. reported revenue of $3.9M.
Does CTOR pay dividends?
Citius Oncology, Inc.. does not currently pay dividends.
Where can I find CTOR SEC filings?
Official SEC filings for Citius Oncology, Inc.. (CIK: 0001851484) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTOR's EPS?
Citius Oncology, Inc.. has a diluted EPS of $-0.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CTOR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Citius Oncology, Inc.. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CTOR stock overvalued or undervalued?
Valuation metrics for CTOR: ROE of -9.5% (sector avg: 15%), net margin of -140.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CTOR stock in 2026?
Our dual AI analysis gives Citius Oncology, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CTOR's free cash flow?
Citius Oncology, Inc..'s operating cash flow is $-7.4M, with capital expenditures of N/A. FCF margin is -186.5%.
How does CTOR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -140.3% (avg: 12%), ROE -9.5% (avg: 15%), current ratio 0.83 (avg: 2).